Real-world results for blockbuster weight-loss meds like Ozempic , Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says. People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity . That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy ( semaglutide ) and Zepbound (tirzepatide) for